Zhukivtsi

This research aims to evaluate whether the group therapy method called I-Reconstruction can help reduce anxiety levels in adults. The study targets individuals with clinically significant anxiety and investigates if emotional stability improves after the therapy. Researchers will compare participants who attend the therapy sessions with those receiving usual care to determine if the new method offers more lasting benefits. The study involves three groups two experimental groups receiving the I-Reconstruction therapy and one control group continuing usual care without intervention. Participants in the therapy groups will attend ten weekly online group sessions, each lasting two hours, led by certified therapists. The therapy focuses on addressing preverbal trauma and internal conflicts related to desire, possession, and satisfaction through psychoeducation, emotional exploration, and group reflection. Participants will be involved in a 17-month process including screening, therapy sessions, and follow-up assessments at 3, 6, and 12 months after completing the therapy. They will complete questionnaires measuring anxiety, depression, internal conflicts, and preverbal dysregulation at multiple time points. The main outcomes include changes in anxiety levels assessed by the Beck Anxiety Inventory and Hospital Anxiety and Depression Scale. The control group will undergo the same assessments without receiving the therapy.

This research aims to collect real-world data on the characteristics, management, healthcare use, and outcomes of patients living with type 2 diabetes, hypertension, heart failure, and chronic kidney disease. It is an international observational registry that includes patients from many countries to better understand how these conditions are treated in everyday clinical practice. Participants in this registry are observed without receiving experimental treatments. Data are collected both retrospectively and prospectively using a cloud-based electronic case report form accessible to investigators and a scientific committee. The registry includes groups of patients with type 2 diabetes, hypertension, chronic kidney disease, or heart failure, either as their primary condition or as a coexisting condition. Patients provide information about their health status, treatments, and outcomes over time. Researchers collect data on demographics, disease characteristics, laboratory tests, treatments, healthcare visits, hospitalizations, and lifestyle factors. The study measures many outcomes such as blood sugar levels, kidney function, heart function, medication use, and health events over an average of three years. Participation is voluntary and ongoing, with data collection continuing until the study end date in 2030.

Researchers are evaluating tulisokibart MK-7240 as a possible treatment for adults with active Psoriatic Arthritis PsA. This Phase 2b study aims to assess the efficacy, safety, and tolerability of different doses of tulisokibart compared to a placebo. The goal is to determine whether any dose of tulisokibart can better reduce PsA symptoms than the placebo over a 16-week period. Participants will be randomly assigned to receive one of several treatments a high dose, medium dose, or low dose of tulisokibart, or a matching placebo. After 16 weeks, those initially on placebo or low dose will be rerandomized to a medium or high dose of tulisokibart. The study includes a 16-week placebo-controlled period followed by a long-term extension lasting up to 112 weeks, which is divided into a 40-week main extension and a 72-week optional extension. During the study, participants will receive the study drug through subcutaneous injections and undergo regular assessments to track symptom changes and safety. Researchers will measure responses such as the American College of Rheumatology 20% improvement criteria at Week 16, along with other clinical responses and patient-reported outcomes. Safety will be monitored throughout the study and extension periods, with participation lasting up to several years.